Table 3.
Univariate analysis of possible prognostic factors of time to progression
| Variable | n | Univariate analysis | ||
|---|---|---|---|---|
| Median survival, Months (95 % CI) | HR (95 % CI) | P value | ||
| Age | ||||
| <65 | 128 | 6.4 (5.3–7.5) | 1.00 | |
| ≥65 | 93 | 6.0 (2.8–9.1) | 0.98 (0.72–1.32) | 0.877 |
| Sex | ||||
| Male | 153 | 6.5 (5.0–7.9) | 1.00 | |
| Female | 68 | 5.5 (3.6–7.3) | 1.15 (0.84–1.59) | 0.390 |
| Obesitya | ||||
| No | 165 | 5.7 (4.1–7.4) | 1.00 | |
| Yes | 56 | 6.2 (5.1–7.4) | 0.98 (0.70–1.39) | 0.923 |
| Charlson comorbidity index score | ||||
| <3 | 133 | 6.0 (4.3–7.6) | 1.00 | |
| ≥3 | 88 | 6.1 (4.7–7.6) | 0.998 (0.74–1.35) | 0.991 |
| ECOG performance status | ||||
| 0 | 38 | 9.0 (5.0–12.9) | 1.00 | 0.594 |
| 1 | 168 | 5.7 (4.6–6.8) | 1.23 (0.83–1.81) | 0.308 |
| 2 | 15 | 5.1 (0.2–10.1) | 1.15 (0.61–2.16) | 0.659 |
| Total bilirubin (mg/dL) | ||||
| ≤1.5 | 179 | 6.1 (5.0–7.3) | 1.00 | |
| >1.5 | 42 | 5.7 (0.4–11.1) | 0.85 (0.58–1.24) | 0.395 |
| Carbohydrate antigen 19-9 | ||||
| ≤300 | 110 | 6.7 (4.9–8.5) | 1.00 | |
| >300 | 111 | 5.1 (3.4–6.8) | 1.23 (0.92–1.66) | 0.171 |
| Carcinoembryonic antigen | ||||
| ≤5 | 146 | 5.8 (4.6–7.1) | 1.00 | |
| >5 | 75 | 6.2 (3.6–8.9) | 0.99 (0.72–1.36) | 0.961 |
| Prothrombin time (%) | ||||
| ≥80 | 190 | 6.2 (4.8–7.7) | 1.00 | |
| <80 | 31 | 5.8 (3.1–8.6) | 1.02 (0.66–1.59) | 0.932 |
| C-reactive protein (mg/dL) | ||||
| ≤2.5 | 114 | 7.4 (4.7–10.0) | 1.00 | |
| >2.5 | 107 | 5.0 (3.7–6.4) | 1.36 (1.01–1.83) | 0.043 |
| Location of tumor | ||||
| Distal | 26 | 7.4 (1.9–12.8) | 1.00 | 0.145 |
| Perihilar | 71 | 6.5 (4.7–8.3) | 0.91 (0.56–1.47) | 0.691 |
| Intrahepatic | 124 | 5.7 (4.0–7.4) | 1.26 (0.80–1.97) | 0.313 |
| Stageb of cholangiocarcinoma | ||||
| III | 56 | 5.8 (4.6–7.1) | 1.00 | |
| IV | 165 | 6.2 (4.8–7.7) | 1.20 (0.85–1.70) | 0.304 |
| Disease status | ||||
| Locally advanced | 84 | 6.0 (4.3–7.6) | 1.00 | |
| Metastatic | 137 | 6.1 (4.6–7.7) | 1.30 (0.96–1.78) | 0.094 |
| Chemotherapy regimen | ||||
| Gemcitabine-based | 179 | 6.7 (5.0–8.4) | 1.00 | |
| 5-fluorouracil-based | 42 | 4.7 (2.2–7.1) | 1.41 (0.99–2.02) | 0.059 |
| Neutrophil–lymphocyte ratio | ||||
| ≤5 | 171 | 6.7 (5.3–8.2) | 1.00 | |
| >5 | 50 | 4.1 (2.4–5.8) | 1.77 (1.23–2.56) | 0.002 |
| Cholecystitis/cholangitis | ||||
| No | 192 | 6.2 (5.0–7.4) | 1.00 | |
| Yes | 29 | 5.5 (2.2–8.7) | 0.93 (0.64–1.51) | 0.928 |
| Biliary decompression | ||||
| No | 102 | 6.5 (5.5–7.5) | 1.00 | |
| Yes | 119 | 5.5 (3.4–7.5) | 0.92 (0.68–1.24) | 0.592 |
| Number of cycles of chemotherapyc | 0.90 (0.86–0.93) | <0.001 | ||
ECOG Eastern Cooperative Oncology Group, HR hazard ratio, CI confidence interval
aObesity was defined as a body mass index >25 kg/m2 according to the Asian-Pacific criteria for obesity
bAll tumors were staged according to the seventh edition of American Joint Committee on Cancer (AJCC) Classification System
cContinuously coded
Significant values are in bold